Pfizer has entered an agreement with Puma Biotechnology, Inc. to out-license development and commercialization of neratinib, an investigational oral, multi-targeted inhibitor of the ErbB1 (EGFR), ErbB2 (HER2) and ErbB4 (HER4) kinases, for the treatment of cancer. Puma will assume responsibility for global development and commercialization of neratinib. Pfizer will be entitled to receive payments based on the achievement of certain development milestones, as well as royalty payments on neratinib...